share_log

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Harris Matthew Scott

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Harris Matthew Scott

Altimmune | 4:持股變動聲明-高管 Harris Matthew Scott
美股SEC公告 ·  08/01 17:41
Moomoo AI 已提取核心訊息
Altimmune's Chief Medical Officer, Harris Matthew Scott, completed a purchase of 1,486 shares of the company's common stock on July 31, 2024. The transaction was carried out at a price of $5.41 per share, resulting in a total investment of $8,039.66. Following this acquisition, Harris now directly holds a total of 55,119 shares in Altimmune. The transaction reflects a direct ownership in the securities and is categorized as a grant, award, or other acquisition as per the transaction code 'A'.
Altimmune's Chief Medical Officer, Harris Matthew Scott, completed a purchase of 1,486 shares of the company's common stock on July 31, 2024. The transaction was carried out at a price of $5.41 per share, resulting in a total investment of $8,039.66. Following this acquisition, Harris now directly holds a total of 55,119 shares in Altimmune. The transaction reflects a direct ownership in the securities and is categorized as a grant, award, or other acquisition as per the transaction code 'A'.
Altimmune的首席醫療官賀錦麗·馬修·斯科特於2024年7月31日購買了1,486股公司普通股。交易價格爲每股5.41美元,總投資爲8,039.66美元。在此次收購之後,賀錦麗直接持有Altimmune的55,119股。該交易反映了對該證券的直接擁有,並根據交易代碼“A”分類爲授予、獎勵或其他收購。
Altimmune的首席醫療官賀錦麗·馬修·斯科特於2024年7月31日購買了1,486股公司普通股。交易價格爲每股5.41美元,總投資爲8,039.66美元。在此次收購之後,賀錦麗直接持有Altimmune的55,119股。該交易反映了對該證券的直接擁有,並根據交易代碼“A”分類爲授予、獎勵或其他收購。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息